Amphastar Pharma (AMPH) Tops Q4 EPS by 7c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral